Table 3 Evaluation of the protein concentration association with muscle function
From: Orthogonal proteomics methods warrant the development of Duchenne muscular dystrophy biomarkers
| Â | Â | Adjusted P-values | ||||
|---|---|---|---|---|---|---|
| Â | Comparisons | MYL3 | CA3 | FGG | LDHB | COL1A1 |
| Â | DMD patients vs. controls | 3.48E-06 | 7.86E-15 | 7.32E-08 | 1.21E-11 | 1.63E-01 |
No age | Ambulant DMD patients vs. controls | 1.67E-06 | 7.34E-14 | 3.03E-07 | 5.88E-11 | 5.62E-01 |
effect | Non-ambulant DMD patients vs. controls | 9.60E-05 | 4.80E-12 | 2.96E-03 | 2.43E-04 | 1.06E-01 |
| Â | Ambulant versus non-ambulant vs. patients | 4.92E-02 | 1.01E-02 | 2.17E-05 | 1.57E-07 | 1.21E-01 |
| Â | DMD patients vs. controls | 1.07E-06 | 5.89E-16 | 4.93E-07 | 4.54E-10 | 4.29E-02 |
Age | Ambulant DMD patients vs. controls | 2.12E-07 | 4.06E-16 | 2.49E-06 | 9.79E-10 | 4.88E-02 |
effect | Non-ambulant DMD patients vs. controls | 1.67E-04 | 1.14E-14 | 9.16E-04 | 2.15E-03 | 1.96E-02 |
| Â | Ambulant versus non-ambulant vs. patients | 7.07E-01 | 9.00E-01 | 8.22E-01 | 2.92E-02 | 9.00E-01 |